Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year Low – Here’s What Happened

Pulse Biosciences, Inc (NASDAQ:PLSE) shares reached a new 52-week low on Monday . The company traded as low as $13.63 and last traded at $13.75, with a volume of 218050 shares traded. The stock had previously closed at $14.40.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Pulse Biosciences presently has an average rating of “Hold” and an average target price of $22.00.

Pulse Biosciences Stock Performance

The company’s 50 day moving average price is $16.97 and its 200-day moving average price is $16.30. The stock has a market cap of $881.69 million, a P/E ratio of -11.51 and a beta of 1.80.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.02.

Insider Buying and Selling

In other Pulse Biosciences news, insider Kevin Patrick Danahy sold 4,600 shares of Pulse Biosciences stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $18.53, for a total value of $85,238.00. Following the sale, the insider owned 43,298 shares of the company’s stock, valued at approximately $802,311.94. The trade was a 9.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Robert W. Duggan bought 34,659 shares of Pulse Biosciences stock in a transaction dated Wednesday, September 10th. The shares were bought at an average cost of $14.66 per share, with a total value of $508,100.94. Following the completion of the transaction, the director directly owned 47,551,200 shares in the company, valued at approximately $697,100,592. This trade represents a 0.07% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders sold 95,000 shares of company stock worth $1,550,380. Insiders own 74.60% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

Several large investors have recently added to or reduced their stakes in PLSE. Portolan Capital Management LLC purchased a new position in Pulse Biosciences in the 3rd quarter valued at approximately $1,809,000. Nuveen LLC purchased a new stake in shares of Pulse Biosciences during the first quarter worth $915,000. Pandora Wealth Inc. bought a new position in shares of Pulse Biosciences in the first quarter worth $828,000. Geode Capital Management LLC grew its holdings in Pulse Biosciences by 7.2% during the 2nd quarter. Geode Capital Management LLC now owns 499,464 shares of the company’s stock valued at $7,538,000 after buying an additional 33,744 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in Pulse Biosciences in the 2nd quarter worth approximately $466,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.